Erika M. Skaggs

This study shows that EZH1/2 inhibition with valemetostat enhances anti-PD1 immunotherapy in lung squamous cell carcinoma by increasing MHC Class II and reprogramming neutrophils.

This study shows that methionine restriction reduces lung cancer progression and enhances chemotherapy response in a mouse model and human cell lines.

EZH2 inhibition increases immune checkpoint inhibitor response in lung squamous cell carcinomas by enhancing antigen presentation and immune cell infiltration.